Global Cholinesterase Inhibitors Market is expected to grow at a CAGR of 5.5% during the forecast period, to reach USD 3.2 billion by 2030 from USD 2.4 billion in 2018. The market is driven by factors such as increasing prevalence of Alzheimer's disease and other neurodegenerative disorders, growing geriatric population, and increasing awareness about the benefits of cholinesterase inhibitors among patients with mild cognitive impairment (MCI). The global cholinesterase inhibitors market is segmented on the basis of type, application, and region. On the basis of type, it is classified into Haboyin (donepezil), Tacrine (rivastigmine), Donepezil (galantamine), Rivastigmine (tacrine) and Galantamine (donepezil). On the basis of application it is classified into Mild Patient, Moderate Patient and Serious Patient. On the basis of region it includes North America, Latin America Europe Asia Pacific Middle East & Africa. -The global Cholinesterase Inhibitors market is expected to grow at a CAGR of XX% during the forecast period. -The global Cholinesterase Inhibitors market is expected to reach $XX billion by 2026, from $XX billion in 2017. -Increasing prevalence of Alzheimer's disease and other neurodegenerative disorders are driving the growth of the global Cholinesterase Inhibitors market. -Increasing geriatric population base and increasing awareness about Alzheimer's disease are also driving the growth of the global Cholinesterase Inhibitors market. -Increasing research and development activities for new drugs in this segment are also driving the growth of this segment globally. -High cost associated with these drugs is restraining their adoption in developing countries such as India, China, Brazil, Mexico etc, which have large populations suffering from neurodegenerative disorders such as Alzheimer's disease.
Industry Growth Insights published a new data on “Cholinesterase Inhibitors Market”. The research report is titled “Cholinesterase Inhibitors Market research by Types (Haboyin, Tacrine, Donepezil, Rivastigmine, Galantamine, Others), By Applications (Mild Patient, Moderate Patient, Serious Patient), By Players/Companies Pfizer, Shionogi Pharma, Daiichi Pharmaceutical Co Ltd, Novartis, F. Hoffmann-La Roche, Merck, Eli Lily & Co, Taloph pharmaceutical, Forward group, Eisai Co., Ltd, ACI HealthCare Limited, Actavis Elizabeth LLC, Alembic pharms Ltd, Aurobindo, Cadila pharms Ltd, Cipla Ltd, CSPC Ouyi, Dexcel pharma, Dr.Reddy's, Heritage Pharma, Hetero Labs Ltd, Indicus Pharma”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Cholinesterase Inhibitors Market Research Report
By Type
Haboyin, Tacrine, Donepezil, Rivastigmine, Galantamine, Others
By Application
Mild Patient, Moderate Patient, Serious Patient
By Companies
Pfizer, Shionogi Pharma, Daiichi Pharmaceutical Co Ltd, Novartis, F. Hoffmann-La Roche, Merck, Eli Lily & Co, Taloph pharmaceutical, Forward group, Eisai Co., Ltd, ACI HealthCare Limited, Actavis Elizabeth LLC, Alembic pharms Ltd, Aurobindo, Cadila pharms Ltd, Cipla Ltd, CSPC Ouyi, Dexcel pharma, Dr.Reddy's, Heritage Pharma, Hetero Labs Ltd, Indicus Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
231
Number of Tables & Figures
162
Customization Available
Yes, the report can be customized as per your need.
Global Cholinesterase Inhibitors Market Report Segments:
The global Cholinesterase Inhibitors market is segmented on the basis of:
Types
Haboyin, Tacrine, Donepezil, Rivastigmine, Galantamine, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Mild Patient, Moderate Patient, Serious Patient
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Shionogi Pharma
- Daiichi Pharmaceutical Co Ltd
- Novartis
- F. Hoffmann-La Roche
- Merck
- Eli Lily & Co
- Taloph pharmaceutical
- Forward group
- Eisai Co., Ltd
- ACI HealthCare Limited
- Actavis Elizabeth LLC
- Alembic pharms Ltd
- Aurobindo
- Cadila pharms Ltd
- Cipla Ltd
- CSPC Ouyi
- Dexcel pharma
- Dr.Reddy's
- Heritage Pharma
- Hetero Labs Ltd
- Indicus Pharma
Highlights of The Cholinesterase Inhibitors Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Haboyin
- Tacrine
- Donepezil
- Rivastigmine
- Galantamine
- Others
- By Application:
- Mild Patient
- Moderate Patient
- Serious Patient
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cholinesterase Inhibitors Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cholinesterase inhibitors are medications that block the breakdown of choline by the enzyme cholinesterase. This can lead to increased levels of choline in the blood, which can improve memory and cognitive function.
Some of the major players in the cholinesterase inhibitors market are Pfizer, Shionogi Pharma, Daiichi Pharmaceutical Co Ltd, Novartis, F. Hoffmann-La Roche, Merck, Eli Lily & Co, Taloph pharmaceutical, Forward group, Eisai Co., Ltd, ACI HealthCare Limited, Actavis Elizabeth LLC, Alembic pharms Ltd, Aurobindo, Cadila pharms Ltd, Cipla Ltd, CSPC Ouyi, Dexcel pharma, Dr.Reddy's, Heritage Pharma, Hetero Labs Ltd, Indicus Pharma.
The cholinesterase inhibitors market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Cholinesterase Inhibitors Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Cholinesterase Inhibitors Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Cholinesterase Inhibitors Market - Supply Chain
4.5. Global Cholinesterase Inhibitors Market Forecast
4.5.1. Cholinesterase Inhibitors Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Cholinesterase Inhibitors Market Size (000 Units) and Y-o-Y Growth
4.5.3. Cholinesterase Inhibitors Market Absolute $ Opportunity
5. Global Cholinesterase Inhibitors Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Cholinesterase Inhibitors Market Size and Volume Forecast by Type
5.3.1. Haboyin
5.3.2. Tacrine
5.3.3. Donepezil
5.3.4. Rivastigmine
5.3.5. Galantamine
5.3.6. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Cholinesterase Inhibitors Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Cholinesterase Inhibitors Market Size and Volume Forecast by Application
6.3.1. Mild Patient
6.3.2. Moderate Patient
6.3.3. Serious Patient
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Cholinesterase Inhibitors Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Cholinesterase Inhibitors Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Cholinesterase Inhibitors Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Cholinesterase Inhibitors Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Cholinesterase Inhibitors Demand Share Forecast, 2019-2026
9. North America Cholinesterase Inhibitors Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Cholinesterase Inhibitors Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Cholinesterase Inhibitors Market Size and Volume Forecast by Application
9.4.1. Mild Patient
9.4.2. Moderate Patient
9.4.3. Serious Patient
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Cholinesterase Inhibitors Market Size and Volume Forecast by Type
9.7.1. Haboyin
9.7.2. Tacrine
9.7.3. Donepezil
9.7.4. Rivastigmine
9.7.5. Galantamine
9.7.6. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Cholinesterase Inhibitors Demand Share Forecast, 2019-2026
10. Latin America Cholinesterase Inhibitors Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Cholinesterase Inhibitors Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Cholinesterase Inhibitors Market Size and Volume Forecast by Application
10.4.1. Mild Patient
10.4.2. Moderate Patient
10.4.3. Serious Patient
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Cholinesterase Inhibitors Market Size and Volume Forecast by Type
10.7.1. Haboyin
10.7.2. Tacrine
10.7.3. Donepezil
10.7.4. Rivastigmine
10.7.5. Galantamine
10.7.6. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Cholinesterase Inhibitors Demand Share Forecast, 2019-2026
11. Europe Cholinesterase Inhibitors Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Cholinesterase Inhibitors Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Cholinesterase Inhibitors Market Size and Volume Forecast by Application
11.4.1. Mild Patient
11.4.2. Moderate Patient
11.4.3. Serious Patient
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Cholinesterase Inhibitors Market Size and Volume Forecast by Type
11.7.1. Haboyin
11.7.2. Tacrine
11.7.3. Donepezil
11.7.4. Rivastigmine
11.7.5. Galantamine
11.7.6. Others
11.8.Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Cholinesterase Inhibitors Demand Share, 2019-2026
12. Asia Pacific Cholinesterase Inhibitors Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Cholinesterase Inhibitors Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Cholinesterase Inhibitors Market Size and Volume Forecast by Application
12.4.1. Mild Patient
12.4.2. Moderate Patient
12.4.3. Serious Patient
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Cholinesterase Inhibitors Market Size and Volume Forecast by Type
12.7.1. Haboyin
12.7.2. Tacrine
12.7.3. Donepezil
12.7.4. Rivastigmine
12.7.5. Galantamine
12.7.6. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Cholinesterase Inhibitors Demand Share, 2019-2026
13. Middle East & Africa Cholinesterase Inhibitors Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Cholinesterase Inhibitors Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Cholinesterase Inhibitors Market Size and Volume Forecast by Application
13.4.1. Mild Patient
13.4.2. Moderate Patient
13.4.3. Serious Patient
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Cholinesterase Inhibitors Market Size and Volume Forecast by Type
13.7.1. Haboyin
13.7.2. Tacrine
13.7.3. Donepezil
13.7.4. Rivastigmine
13.7.5. Galantamine
13.7.6. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Cholinesterase Inhibitors Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Cholinesterase Inhibitors Market: Market Share Analysis
14.2. Cholinesterase Inhibitors Distributors and Customers
14.3. Cholinesterase Inhibitors Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Shionogi Pharma
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Daiichi Pharmaceutical Co Ltd
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Novartis
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. F. Hoffmann-La Roche
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Merck
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Eli Lily & Co
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Taloph pharmaceutical
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Forward group
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Eisai Co., Ltd
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. ACI HealthCare Limited
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Actavis Elizabeth LLC
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Alembic pharms Ltd
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Aurobindo
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Cadila pharms Ltd
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Cipla Ltd
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. CSPC Ouyi
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Dexcel pharma
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. Dr.Reddy's
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. Heritage Pharma
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook